NEW YORK, Sept. 9 /PRNewswire-FirstCall/ -- NeoStem, Inc. which is pioneering the pre-disease collection, processing and long-term storage of adult stem cells for future medical need, announced today that Alan Harris, M.D., Ph.D., the Company's Vice President of Drug Development and Regulatory Affairs, will speak at a conference on Clinical Applications for Age Management Medicine, taking place in Las Vegas, November 5-8, 2009.
Apheresis utilizes a minimally invasive procedure that members of NeoStem's collection network employ to collect stem cells from peripheral blood to store, using NeoStem's proprietary cryogenic technology, for the donor's personal use in time of medical need. NeoStem also holds a worldwide exclusive license to VSEL (Very Small Embryonic-Like) Cell Technology, and is supporting research programs at the University of Louisville as well as engaging in its own research and development activities. As Vice President of Drug Development and Regulatory Affairs, Dr. Harris oversees the Company's progress in these cutting edge arenas.
Age management medicine is a proactive, preventive approach focused on preservation of optimum human function and quality of life, making every effort to modulate the process of aging prior to the onset of degenerative aging. The basic tenets of age management medicine are patient evaluation through extensive medical history, lifestyle assessment, physical examination and laboratory evaluation to establish personalized proactive treatment plans consisting of proper diet, exercise, stress management and appropriate medical interventions.
NeoStem is developing a network of adult stem cell collection centers that are focused on enabling people to donate and store their own (autologous) stem cells when they are young and healthy for their personal use in times of future medical need. The Company has also entered into research and development through the acquisition of a worldwide exclusive license to technology to identify and isolate VSELs (very small embryonic-like stem cells), which have been shown to have several physical characteristics that are generally found in embryonic stem cells and is pursuing other technologies to advance its position in the field of stem cell tissue regeneration. In 2009, the Company began to expand its operations into China in connection with the development of therapeutic adult stem cell technologies and is seeking to generate revenues through its regenerative medicine programs and technologies in China. For more information, please visit: www.neostem.com.
Forward-Looking Statements
NeoStem, Inc.
